Healthcare

Pediatric Health Care Products and Services

Publication Date	March 2009
Publisher	BCC Research
Product Type	Report
Pages	213
ISBN Number	not applicable
Product Code	BCC00103

Price

£3,205.00
approximately: $4,853 | €3,577

pdf

print £2,935 ($4,444 | €3,276)

Order above formats by FAX

Pediatricians are confronted daily with a variety of short-term illnesses such as upper respiratory infections, ear infections and gastrointestinal illnesses. While these illnesses are transient in nature, they also present a significant drain on time and financial resources for parents and others involved with the primary care of the child. While most short-term illnesses are treatable and subside within one to five days, chronic illnesses are far more costly and damaging for the children, families and other caregivers. Chronic illnesses can include respiratory illnesses, cystic fibrosis, diabetes, obesity, malnutrition, cerebral palsy, neurological illnesses, depression and epilepsy/seizures.

This BCC Research report off ers a comprehensive picture of trends in the current global pediatric healthcare industry, and makes market projections to the end of 2013. It covers short-term and chronic illnesses and includes information on prescription drugs, immunizations, services and medical devices. Also included are products within the pharmaceutical pipeline and research into alternative treatment modalities such as herbal formulations. Profiles of leading companies involved with pediatric care are provided. Information on company placement within the market and strategic analyses of the company's available and emerging products are discussed.

The scope of this report is broad and includes:

Descriptions of the major product segments including respiratory, neurological and gastrointestinal, with the pharmaceuticals that accompany each segment
The current global market status for pediatric healthcare, with trends and forecasts for growth through 2013
Discussion of chronic pediatric conditions such as allergies, attention deficit disorders, asthma, autism spectrum disorders, diabetes and obesity
Analysis of social factors that affect pediatric health such as prenatal care, malnutrition and health insurance
Company profiles.

Why you should buy this report:

To understand the full scope of the pediatric market including applicable illnesses, products and procedures, and the latest research regarding pharmaceuticals and diagnostics
To learn about evolving treatment protocols for chronic pediatric illnesses such as asthma and allergies, cystic fi brosis, diabetes, obesity, malnutrition, cerebral palsy, attention deficit hyperactivity disorder, depression, epilepsy/seizures, and illnesses resulting from low birth weight
To develop competitive marketing plans around products in the pharmaceutical pipeline and research into alternative treatment modalities such as herbal formulations.

Chapter One: Introduction
- Study Goal And Objectives
- Reasons For Doing The Study
- Intended Audience
- Scope Of Report
- Information Sources
- Analysts Credentials
- Related Bcc Publications
- Bcc Online Services
- Disclaimer
Chapter Two: Summary
- Projected Growth Of Pediatric Markets
  - Summary Table Global Trends In Pediatric Health Care, Through 2013 ($ Millions)
  - Summary Figure Global Trends In Pediatric Health Care, Based On Condition, 2007-2013 ($ Millions)
- Market Forecasts For Short-Term Illnesses
  - Rotavirus
  - Ear Infections
  - Upper Respiratory Infections
- Market Forecasts For Chronic Illnesses
  - Allergies
  - Attention Deficit Disorders
  - Asthma
  - Autism Spectrum Disorders
  - Diabetes
  - Obesity
Chapter Three: Overview Of The Pediatric Healthcare Industry
- Prenatal Care/Implications
  - International Prenatal Care/Implications
    - Low Birth Weight
- Newborn Care
  - Care In The U S.
  - International Newborn Care
    - Malnutrition
- Children Age 1 To 6
- Children Age 7 To 12
- Adolescent Children Age 13 To 18
- Adolescent Reproductive Health
  - Sexually Transmitted Diseases
    - Human Papillomavirus (Hpv)
- Vaccines/Immunizations
  - Table 2 Immunization Schedule For Children From Birth To 6 Months
  - Table 3 Immunization Schedule For Children From Months To 4 To 6 Years
  - Table 4 Immunization Schedule For Children And Adolescents From 7 To 18
  - Vaccine Efficacy And Controversy
- Implications For Future Developments In The U S.
Chapter Four: Short-Term Illnesses In The Pediatric Population
- Otitis Media (Ear Infections)
  - Causes Of Otitis Media
    - Allergies
    - Infection
    - Blockage
    - Nutrition And Breastfeeding
  - Types And Symptoms
  - Treatment
    - Pharmacological Intervention
      - Use Of Prevnar
      - Table 6 Global Prescription Costs For Treatment Of Pediatric Otitis Media, Through 2013 ($ Millions)
      - Table 7 Prescription Costs For Treatment Of Pediatric Otitis Media, In The U S , Through 2013 ($ Millions)
    - Surgical Intervention
      - Myringotomy
      - Table 8 Global Surgical Costs For Myringotomy In Pediatric Patients, Through 2013 ($ Millions)
      - Table 9 Surgical Costs For Myringotomy In U S Pediatric Patients, Through 2013 ($ Millions)
      - Adenoidectomy And Tonsillectomy
      - Table 10 Global Surgical Costs For Tonsillectomy/Adenoidectomy In Pediatric Patients, Through 2013 ($ Millions)
      - Table 11 Surgical Costs For Tonsillectomy/Adenoidectomy In U S. Pediatric Patients, Through 2013 ($ Millions)
- Gastrointestinal Illnesses
  - Rotavirus
    - Transmission
    - Symptoms
    - Treatment
      - Dehydration
      - Zinc
    - Vaccinations
    - Rotateq
    - Rotarix
    - Table 12 Global Vaccination For Pediatric Rotovirus, Through 2013 ($ Millions)
    - Table 13 U S. Vaccination For Pediatric Rotovirus, Through 2013 ($ Millions)
  - Gastroesophageal Reflux
    - Treatment
      - Eliminate Symptoms
      - Heal Esophagus
      - Prevent Complications
      - Table 14 Current Treatments For Gerd
- Upper Respiratory Infections
  - Table 15 Global Direct Costs Of Pediatric Upper Respiratory Infections, Through 2013 ($ Millions)
  - Table 16 Direct Costs For Pediatric Upper Respiratory Infections In The U S, Through 2013 ($ Millions)
  - Causes And Symptoms
  - Table 17 Common Symptoms Of An Uri
  - Treatments
    - Increased Fluid Intake
    - Second-Hand Smoke
    - Medications
  - Antibiotic Treatments
    - Withdrawing Medicines
  - Complications
Chapter Five: Chronic Illnesses In The Pediatric Population
- Table 18 Global Cost Of Chronic Illnesses In The Pediatric Population, Through 2013 ($ Millions)
- Table 19 Cost Of Chronic Illnesses In U S. Pediatric Population, Through 2013 ($ Millions)
- Figure 2 Projected Costs For Pediatric Chronic Illnesses In The U S , Through 2013 ($ Millions)
- Cystic Fibrosis
  - Origins Of The Disease
  - Diagnosing Cf
  - Prevalence
  - Treatment
    - Oscillating Positive Expiratory Pressure (Pep)
    - High-Frequency Chest Wall Oscillation (Hfcwo)
    - Medications
      - Pulmozyme
      - Tobi
    - Enzyme Treatments
      - Table 20 Global Sales For Pediatric Cystic Fibrosis Medications And Therapies, Through 2013 ($ Millions)
      - Table 21 U S. Sales For Pediatric Cystic Fibrosis Medications And Therapies, Through 2013 ($ Millions)
      - Table 22 U S. Sales For Cystic Fibrosis Medications, By Company, Through 2013 ($ Millions)
    - Antibiotics
- Diabetes
  - History
  - Origins Of The Disease
  - Type 1 Diabetes
  - Type 2 Diabetes
  - Complications
    - Hypoglycemia
    - Hyperglycemia
    - Ketoacidosis
  - Diagnosing Diabetes
    - Type 1 Diagnosis
    - Type 2 Diagnosis
    - Prediabetes
  - Prevalence
  - Complications Of Pediatric Diabetes
    - Growth
    - Psychological Characteristics
    - Health Status
    - Family Dynamics
    - Outside Care
  - Treatments
    - Glycemic Control
    - Types Of Insulin
      - Long-Acting Insulins
      - Rapid Insulins
      - Intermediate-Acting Insulin
      - Short-Acting Insulin
  - Alternative Treatment For Type 2 Diabetes
    - Alternative Delivery Options
      - Insulin Pump
      - Insulin Pens
      - Inhaled Insulin
        
        Table 23 Global Insulin Market, Through 2013 ($ Millions)
        
        Table 24 Insulin Market In U S , Through 2013 ($ Millions)
        
        Table 25 Insulin Approved For Children And Adolescents In The U S.
        
        Table 26 Global Pediatric Insulin Market, Through ($ Millions)
        
        Table 27 Pediatric Insulin Market In U S , Through 2013 ($ Millions)
  - Oral Agents
    - Table 28 Selected list Of Most Commonly Prescribed Oral Agents
  - Nutritional Management
  - Physical Activity
  - Glucose Monitoring Systems
    - Table 29 Selected list Of Companies Marketing Glucose Monitoring Tests
    - Abbott Laboratories New Technology
    - Table 30 Worldwide Market For Blood Glucose Monitoring Devices, Through 2013 ($ Millions)
    - Table 31 U S. Blood Glucose Monitoring Market, Through 2013 ($ Millions)
    - Table 32 Selected Global Blood Glucose Monitoring Market By Company, Through 2013 ($ Millions)
    - Pediatric Market
    - Table 33 Global Pediatric Blood Glucose Monitoring Market, Through 2013 ($ Millions)
    - Table 34 U S. Pediatric Blood Glucose Monitoring Market, Through 2013 ($ Millions)
- Low-Birth Weight
  - Origins Of The Disease
  - Prevalence
    - Consequences In The U S.
    - Neurological Problems
    - Chronic Lung Disease
    - Hearing Loss
    - Retinopathy Of Prematurity
  - Diagnosing Low Birth Weight
  - Treatment For Low Birth Weight
    - Retinopathy
  - Costs Of Low Birth-Weight Children
- Malnutrition
  - Origins Of The Disease
  - Diagnosing Malnutrition
  - Micronutrient Deficiencies
    - Table 35 Effects Of Micronutrient Deficiencies
    - Vitamin A Deficiency
    - Iron Deficiency
    - Iodine Deficiency
    - Folic Acid
  - Prevalence
  - Treatments
  - Addressing Malnutrition In The U S.
    - Successful National Nutrition Programs
      - Supplemental Nutrition Assistance Program (Snap)
      - Women, Infants And Children (Wic)
  - Addressing Malnutrition Globally
    - Nutriset
      - Table 36 Projected Sales Of Plumpynut, Through 2013 ($ Millions)
- Neurological Disorders
- Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder
  - Origins Of Adhd
    - Brain Structures And Chemicals
    - Genetic Factors
    - Dietary Factors
  - Prevalence
  - Diagnosing Attention Deficit/Attention Deficit/Hyperactivity Disorders
    - Table 37 Common Symptoms Of Adhd
  - Other Disorders
    - Table 38 Additional Disorders Seen In Children With Adhd
  - Treatment Types
    - Therapy
    - Pharmaceutical Treatments
      - Psychostimulant Medication
      - Non-Stimulant Medication
      - Antidepressant/Antianxiety Medications
      - Antipsychotic Medication
      - Mood Stabilizing Medication
      - Table 39 Selected Prescription Medications For Treating Adhd
      - Table 40 Prescription Medications For Treating Adhd, In Children Under Age 18
    - Global Market For Adhd Treatments
      - Table 41 Global Market For Prescription Adhd Medications, Through 2013 ($ Mllions)
      - Table 42 Global Market For Pediatric Prescription Adhd Medication, Through 2013
    - U S. Market For Adhd Treatments
      - Table 43 U S. Market For Prescription Adhd Medications, Through 2013 ($ Millions)
      - Table 44 U S. Market For Pediatric Prescription Adhd Medications, Through 2013 ($ Millions)
- Autism Spectrum Disorders
  - Autism
    - Table 45 Symptoms Of Autism
  - Aspergers Disorder
  - Childhood Disintegrative Disorder
  - Retts Syndrome
  - Pervasive Developmental Disorder Not Otherwise Specified
  - Origins Of Autism Spectrum Disorders
    - Genetics
    - Rejected Origins Of Autism Spectrum Disorders
    - Environmental Factors
  - Prevalence
  - Diagnosing Asd
  - Treatment For Asd
    - Psychoeducational Treatment
    - Medical Treatment
      - Dietary Changes
      - Vitamin Therapy
      - Risperidone
  - Economic Impact Of Autism
    - Table 46 Global Direct Costs Of Autism Treatments And Medications, Through 2013 ($ Millions)
    - Table 47 Global Direct Costs Of Autism Treatments And Medications In The Pediatric Population, Through 2013 ($ Millions)
    - Table 48 U S. Direct Costs Of Autism Treatments And Medication In Pediatric Population, Through 2013 ($ Millions)
- Cerebral Palsy
  - Origins Of The Disorder
  - Diagnosing Cerebral Palsy
  - Prevalence Of Cp
    - Table 49 U S. Average lifetime Cerebral Palsy Costs Per Person, Through 2013 ($ Millions)
    - Table 50 Global Average Costs For Pediatric Cp Patients Up To Age 18, Through 2013 ($ Millions)
    - Table 51 U S. Average Costs For Pediatric Cp Patients Upto Age 18, Through 2013 ($ Millions)
  - Treatment Of Cerebral Palsy
    - Therapies
    - Surgical Procedures
    - Medications
    - Table 52 Medications For Cp Patients
    - Magnesium Sulfate
- Depression
  - Origins Of The Disease
    - Genetic Factors
    - Biological Factors
    - Sociological Factors
    - Psychological Factors
    - Risk Factors For Depression
      - Gender
      - Age
      - Marital Status
      - Family History
      - Parental Deprivation
      - Social Support
      - Family Type
      - Types Of Depression
  - Prevalance Of The Disorder
  - Diagnosing Depression
    - Table 53 Symptoms Of Depression
  - Treatment For Depression
    - Table 54 Global Direct And Indirect Cost Of Depression, Through 2013 ($ Billions)
    - Therapy
    - Antidepressant Medications
    - Table 55 Antidepressant Medications Appropriate For Pediatric Patients
    - Government Warnings
    - Table 56 Global Cost Of Antidepressant Medications In Pediatric Population, Through 2013 ($ Millions)
    - Table 57 Cost Of Antidepressant Medication In The U S Pediatric Population, Through 2013 ($ Millions)
- Epilepsy/Seizures
  - Origins Of The Disease
    - Inherited Genetic Causes
    - Congenital Causes
    - Acquired
    - Table 58 Potential Causes Of Epilepsy, By Age
  - Diagnosing Epilepsy
  - Table 59 International Classification Of Epileptic Seizures
  - Prevalence
  - Treatments
    - Anti-Epileptic Medications
    - Table 60 Selected Current Medications For Epilepsy
    - Table 61 Projected Global Direct Costs Of Epilepsy Mediations, Through 2013 ($ Millions)
    - Table 62 Projected Global Pediatric Direct Costs Of Epilepsy Medications, Through 2013 ($ Millions)
    - Table 63 Projected U S. Direct Costs Of Epilepsy, Through 2013 ($ Millions)
    - Table 64 Projected Direct Costs For The U S. Pediatric Epilepsy Population, Through 2013 ($ Millions)
    - Vagus Nerve Stimulation
    - Surgical Options
    - The Future
- Obesity
  - Table 65 Projected U S. Pediatric Direct Healthcare Costs Attributable To Overweight And Obesity, Through 2013 ($ Millions)
  - Origins Of The Disease
  - Diagnosing Obesity
    - Genetic Factors
    - Environmental Factors
    - Behavioral Factors
  - Prevalence Of The Disease
  - Treatment Of Obesity
    - Healthy Food Choices
    - Dietary Restrictions
    - Increased Exercise
    - Pharmaceutical Products For Adolescents
    - Table 66 Global Market For Prescription Weight Loss Products Through 2013 ($ Millions)
    - Table 67 Global Market For Prescription Weight Loss Products For Adolescents, Through 2013 ($ Millions)
    - Table 68 U S Market For Prescription Weight Loss Products For Adolescents, Through 2013 ($ Millions)
    - Surgical Options
    - Table 69 Recommended Criteria For Bariatric Surgery For Adolescents
    - Table 70 Global Market For Surgical Proceduresfor Pediatric Patients Who Are Obese/Overweight, Through 2013 ($ Millions)
    - Table 71 Market For Surgical Procedures For U S Pediatric Patients Who Are Obese/Overweight, Through 2013 ($ Millions)
    - Complications
  - Global Trends
  - Table 72 Projected Global Pediatric Direct Healthcare Costs Attributable To Overweight And Obesity ($ Millions)
- Respiratory Illnesses
- Allergies
  - Origins Of The Disease
    - Airborne Allergies
    - Food Allergies
    - Table 73 Common Food Allergens
    - Sinusitis
    - Drug Allergy
    - Allergic Rhinitis
      - Diagnosing Breathing Allergies
      - Prevalence Of Allergic Rhinitis
  - Treatment
    - Immunotherapy
    - Environmental Measures
    - Antihistamines
      - Cetirizine
      - Fexofenadine
      - Desloratadine
      - Loratadine
    - Mast Cell Stabilizers
      - Anti-Ige Antibody
      - Table 74 Common Allergy Medications Appropriate For Children
  - Costs
  - Table 75 Global Direct Costs Of Allergies, Through ($ Millions)
  - Table 76 Direct Costs Of Allergies In The U S , Through 2013 ($ Millions)
  - Table 77 Global Direct Costs Of Pediatric Allergies, Through 2013 ($ Millions)
  - Table 78 Direct Costs Of U S. Pediatric Allergies, Through 2013 ($ Millions)
- Asthma
  - Origins Of The Disease
  - Diagnosing Asthma
    - Exercise
    - Infections
    - Allergies
    - Irritants
    - Weather
    - Emotions
  - Prevalence Of Asthma
  - Treatments
  - Table 79 Four-Step Guidelines For Treating Asthma In Children Under The Age Of Five
  - Table 80 Four-Step Guidelines For Treating Asthma In Children Over The Age Of Five
  - Table 81 Quick-Acting Medications For Asthma
    - Inhaled Corticosteroids
    - Table 82 Selected listing Of Inhaled Corticosteroids
  - Costs
  - Table 83 Global Costs For Asthma Medications, Through 2013 ($ Millions)
  - Table 84 U S. Costs For Asthma Medications, Through 2013 ($ Millions)
  - Table 85 Global Costs For Pediatric Asthma Medications, Through 2013 ($ Millions)
  - Table 86 Costs For Pediatric Asthma Medications In The U S , Through 2013 ($ Millions)
Chapter Six: Current Research
- Allergies
  - Schering-Plough
    - Allergy Immunotherapy
- Asthma
  - 7tm
  - Genentech
    - Xolair
    - Anti-Il13
  - Astrazeneca
    - Medimmune
      - Anti-Il13 Mab (Cat-354)
      - Anti-Il9 Mab (Medi 528)
  - Map Pharmaceuticals
  - Schering-Plough
    - Nasal Inhaled Combinations
    - Pleconaril
  - Asthmatx
    - Bronchial Thermoplasty
  - Topigen Pharmaceuticals
  - Synairgen
  - Vectura Plc
- Attention Deficit/Attention Deficit Hyperactivity Disorder
  - Shire Us
    - Intuniv
  - Somerset Pharmaceuticals
    - Selegiline
  - Cephalon
    - Modafinil
- Cerebral Palsy
  - Genetic Causes Of Cp
  - Stem Cell Research
- Cystic Fibrosis
  - Gene Therapy
    - Copernicus Therapeutics
  - Infections
    - Aradigm Corp
  - Enzyme Replacement
    - Altus Pharmaceuticals
    - Eurand
  - Improved Hydration/Salt Transport
    - Lantiobio, Inc.
    - Sucampo Pharmaceuticals
    - Inspire Pharmaceuticals
    - Pharmaxis
    - Gilead Sciences
  - Protein Production
    - Ptc Therapeutics
    - Vertex Pharmaceuticals
  - Inhalation Therapy
    - Vectura Plc
- Depression
  - Forest Laboratories
    - F2695
    - Lexapro
  - Sanofi Aventis
    - Saredutant
  - Sepracor
    - Sep-225289
    - Sep-227162
- Diabetes
  - Inhalation Insulin
    - Generex Biotechnology
    - Coromed, Inc.
    - Nastech Pharmaceuticals
    - Mannkind Corporation
    - Map Pharmaceuticals
    - Vectura Plc
  - Transdermal Insulin Delivery
    - Dermasonics
    - Medingo
    - Vyteris
  - Blood Glucose Monitoring
    - Abbott Laboratories
  - Longer-Lasting Insulins
    - Novo Nordisk
  - Forest Laboratories
  - Combination Drug Therapies
    - Novartis/Pfizer
      - Gleevec/Sutent
    - Merck
      - Januvia/Metformin
  - Oral Diabetic Agents
    - Generex Biotechnology
- Ear Infections
- Epilepsy/Seizures
  - Ucb Pharmaceuticals
    - Brivaracetam
  - Johnson & Johnson
    - Carisbamate( Rwj-333369)
  - 2 Dioxy-D-Glucose Research
  - Sepracor
    - Eslicarbanzepine Acetate (Bia-2-093)
  - Schwarz Biosciences
    - Lacosamide
  - Jazz Pharmaceuticals
    - Jzp-4
  - Huperzine A
  - Neuroadjuvants
    - Nax-5055
    - Propylisopropylacetamide (Pid)
  - Marinus Pharmaceuticals
    - Ganaxolone
  - Valeant Pharmaceuticals
    - Retigabine
  - Taro Pharmaceuticals
    - T-2000
- Obesity
  - Drugs Marketed For Other Conditions
  - Obesity Drug Pipeline
    - Sanofi Aventis
    - Phytopharm
    - Arena Pharma
    - 7tm
Chapter Seven: Company Profiles
- 7tm Pharma A/S
  - Business Overview
  - Financial Overview
  - Products
- Abbott Laboratories
  - Abbott Laboratories
  - Financial Information
  - Products
- Altus Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Aradigm Corporation
  - Business Overview
  - Financial Information
  - Products
- Arena Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Astrazeneca Plc
  - Business Overview
  - Financials
  - Products
- Avontec Gmbh
  - Business Overview
  - Financial Information
  - Products
- Axcan Pharma Usa
  - Business Overview
  - Financial Information
  - Products
- Bayer Ag (Miles-Bayer)
  - Business Overview
  - Financial Information
  - Products
- Chiesi Farmaceutici S P A
  - Business Overview
  - Financial Information
  - Products
- Copernicus Therapeutics, Inc
  - Business Overview
  - Financial Information
  - Products
- Coromed, Inc.
  - Business Overview
  - Financial Information
  - Products
- Eli lilly
  - Business Overview
  - Financial Information
  - Products
- Eurand Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Genentech Inc
  - Business Overview
  - Financial Information
  - Products
- Generex Biotechnology
  - Business Overview
  - Financial Information
  - Products
- Gilead Sciences
  - Business Overview
  - Financial Information
  - Products
- Glaxosmithkline Plc
  - Business Overview
  - Financial Information
  - Products
- Inspire Pharmaceuticals, Inc
  - Business Overview
  - Financial Information
  - Products
- Johnson & Johnson
  - Business Overview
  - Financial Information
  - Products
- Kalobios Pharmaceuticals, Inc.
  - Business Overview
  - Financial Information
  - Products
- Lantibio, Inc.
  - Business Overview
  - Financial Information
  - Products
- Mannkind Corp.
  - Business Overview
  - Financial Information
  - Products
- Map Pharmaeuticals
  - Business Overview
  - Financial Information
  - Products
- Merck & Co Inc
  - Business Overview
  - Financial Information
  - Products
- Novartis Ag
  - Business Overview
  - Financial Information
  - Products
- Novo Nordisk
  - Business Overview
  - Financial Overview
  - Products
- Nutriset
  - Business Overview
  - Financial Overview
  - Products
- Pfizer
  - Business Overview
  - Financial Information
  - Products
- Pharmaxis, Ltd
  - Business Overview
  - Financial Informaiton
  - Products
- Phytopharm, Plc
  - Business Overview
  - Financial Information
  - Products
- Ptc Therapeutics
  - Business Overview
  - Financial Information
  - Products
- Roche Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Sanofi-Aventis
  - Business Overview
  - Fianancial Information
  - Products
- Schering-Plough
  - Business Overview
  - Financial Information
  - Products
- Sepracor
  - Business Overview
  - Financial Information
  - Products
- Shire U S.
  - Business Overview
  - Financial Information
  - Products
- Solvay Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Sucampo Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Synairgen Plc
  - Business Overview
  - Financial Information
  - Products
- Topigen Pharmaceuticals Inc.
  - Business Overview
  - Financial Information
  - Products
- Ucb Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Vectura Group Plc
  - Business Overview
  - Financial Information
  - Products
- Vertex Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Wyeth
  - Business Overview
  - Financial Information
  - Products
Appendix: Selected Pediatric Products By Illness
Table 87 Selected Pediatric Products By Illness